Key Highlights

• An FDA advisory panel backed Grail's Galleri test, which screens blood for fragments of DNA shed by tumors.

• In a UK trial of more than 140,000 people, Galleri detected about 14% of Stage 1 cancers versus 60% of Stage 4 cancers.

• A law passed this year created a pathway for Medicare to cover multi-cancer screening tests starting as early as 2029, without guaranteeing payment.

• Grail sells about 250,000 tests this year, mostly in a niche cash market, up from about 180,000 last year.

A Step Toward Multi-Cancer Screening

Cancer is still caught one organ at a time, and only a handful of cancers have any screening test at all. A blood test that could screen for dozens of cancers at once would be a major step. That prospect moved closer last week when a Food and Drug Administration advisory panel backed Grail's Galleri multi-cancer test.

Grail's stock has risen past Wall Street's average price target and has nearly doubled over the past month. The harder question, as one analysis frames it, is that finding cancer is one thing, while finding it early enough to save lives and justify broad payer coverage is another.

What Galleri Does

For most of medical history, doctors waited for cancer to announce itself with a lump or another symptom and then went looking for it. Screening reversed that approach by seeking cancer before the patient knows it is there, when it is still small enough to treat. Decades of trial and error have produced a short list of tests, such as colonoscopies and mammograms, that work, and they cover only a few cancers.

Grail spent a decade and billions of dollars trying to fill that gap. Galleri scans blood for fragments of DNA shed by tumors, and it looks most promising where medicine is least equipped, in cancers such as pancreatic, ovarian and liver cancer, which have no routine screening.

What the Trial Showed

Advanced tumors shed more DNA and are therefore easier to detect. In a UK trial of more than 140,000 people, Galleri detected about 14% of Stage 1 cancers, compared with 60% of Stage 4 cancers. The trial missed its main goal of cutting the number of cancers caught in Stage 3 and Stage 4 combined. Stage 4 diagnoses fell, but Stage 3 diagnoses rose, possibly because cancers were being caught earlier. Overall, late-stage cancers were not reduced.

That leaves a central question open: whether Galleri finds cancer early and consistently enough to change patient outcomes. The FDA itself asked its advisers whether calling it an "early" detection test was justified. The answer matters because screening healthy people carries risks. A false positive can send someone into scans and biopsies they never needed, and a false negative can create false reassurance. The balance is between those risks and the fact that some people find their cancer earlier.

The Medicare Question

The FDA usually follows its advisory panels. The larger commercial prize is insurance coverage, particularly from Medicare. A law passed this year created a pathway for Medicare to cover multi-cancer screening tests starting as early as 2029, but it did not guarantee payment. The Centers for Medicare and Medicaid Services still has to decide whether a test is reasonable and necessary.

An analyst at a research firm built a model in which Grail's stock is worth about USD 50 without Medicare coverage and USD 150 with it. With the stock trading around USD 150, the analyst noted, it is priced for almost the entire upside in her model, as though coverage were close to certain, while she puts the odds closer to a coin flip.

Possible Outcomes

An outright rejection would be politically fraught, but an approval could come with conditions. A former Medicare chief medical officer who advises Grail noted that the agency could opt for "coverage with evidence development," a policy he helped design, which pays for promising tests or treatments on condition that data is systematically collected on all treated patients.

Even a favorable ruling would build a market only gradually. Coverage would not begin until 2029, at first only for people aged 50 to 65, with the upper limit rising one year at a time after that. An analyst at an investment bank said a Medicare decision, especially alongside backing from guideline groups such as the American Cancer Society, is what tends to open the commercial market.

The Cash Market Today

For now, Grail relies on a niche cash market. It sells about 250,000 tests this year, mostly to what the analyst calls the "worried, wealthy and well," compared with about 180,000 last year. The company is projected to post annual losses of hundreds of millions of dollars through the end of the decade, and a fresh capital raise is described as almost inevitable.

Grail also does not have the field to itself. Abbott, Natera and Guardant Health are developing tests of their own.

Decision Points

The FDA's decision following the panel vote, the CMS ruling on whether the test is reasonable and necessary, and the conditions attached to any Medicare coverage from 2029 are the markers for Galleri's path.